Literature DB >> 19464919

The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.

Virginia Tirino1, Rosa Camerlingo, Renato Franco, Donatella Malanga, Antonello La Rocca, Giuseppe Viglietto, Gaetano Rocco, Giuseppe Pirozzi.   

Abstract

OBJECTIVE: Emerging evidence suggests that specific sub-populations of cancer cells with stem cell characteristics within the bulk of tumours are implicated in the pathogenesis of heterogeneous malignant tumours. The cells that drive tumour growth have been denoted cancer-initiating cells or cancer stem cells (hereafter CSCs). CSCs have been isolated initially from leukaemias and subsequently from several solid tumours including brain, breast, prostate, colon and lung cancer. This study aimed at isolating and characterising the population of tumour-initiating cells in non-small-cell lung cancer (NSCLC).
METHODS: Specimens of NSCLC obtained from 89 patients undergoing tumour resection at the Cancer National Institute of Naples were analysed. Three methods to isolate the tumour-initiating cells were used: (1) flow cytometry analysis for identification of positive cells for surface markers such as CD24, CD29, CD31, CD34, CD44, CD133 and CD326; (2) Hoechst 33342 dye exclusion test for the identification of a side-population characteristic for the presence of stem cells; (3) non-adherent culture condition able to form spheres with stem cell-like characteristics. Definition of the tumourigenic potential of the cells through soft agar assay and injection into NOD/SCID mice were used to functionally define (in vitro and in vivo) putative CSCs isolated from NSCLC samples.
RESULTS: Upon flow cytometry analysis of NSCLC samples, CD133-positive cells were found in 72% of 89 fresh specimens analysed and, on average, represented 6% of the total cells. Moreover, the number of CD133-positive cells increased markedly when the cells, isolated from NSCLC specimens, were grown as spheres in non-adherent culture conditions. Cells from NSCLC, grown as spheres, when assayed in soft agar, give rise to a 3.8-fold larger number of colonies in culture and are more tumourigenic in non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice compared with the corresponding adherent cells.
CONCLUSIONS: We have isolated and characterised a population of CD133-positive cells from NSCLC that is able to give rise to spheres and can act as tumour-initiating cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19464919     DOI: 10.1016/j.ejcts.2009.03.063

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  89 in total

1.  CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.

Authors:  Junwei Chen; Tianhua Guo; Lei Zhang; Li-Xuan Qin; Samuel Singer; Robert G Maki; Takahiro Taguchi; Ronald Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2011-11-10       Impact factor: 5.006

Review 2.  The role of human aldehyde dehydrogenase in normal and cancer stem cells.

Authors:  Irene Ma; Alison L Allan
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

3.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

Review 4.  Cancer stem cell detection and isolation.

Authors:  Meysam Moghbeli; Faezeh Moghbeli; Mohammad Mahdi Forghanifard; Mohammad Reza Abbaszadegan
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

5.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Ivan Bertoncello; Zea Borok; Carla Kim; Angela Panoskaltsis-Mortari; Susan Reynolds; Mauricio Rojas; Barry Stripp; David Warburton; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2011-06

6.  Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.

Authors:  Elham Kalantari; Mojgan Asgari; Seyedehmoozhan Nikpanah; Naghme Salarieh; Mohammad Hossein Asadi Lari; Zahra Madjd
Journal:  Pathol Oncol Res       Date:  2017-01-12       Impact factor: 3.201

7.  Circulating tumor cells as emerging tumor biomarkers in lung cancer.

Authors:  Renato Franco; Monica Cantile; Federica Zito Marino; Giuseppe Pirozzi
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

Review 8.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

9.  High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis.

Authors:  Kyungeun Kim; Hyojin Ihm; Jae Y Ro; Yong Mee Cho
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

10.  Lung cancer stem cell: new insights on experimental models and preclinical data.

Authors:  Caroline Rivera; Sofia Rivera; Yohann Loriot; Marie-Catherine Vozenin; Eric Deutsch
Journal:  J Oncol       Date:  2010-12-16       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.